{"slug":"tirzepatide-nerve-damage","verification":{"valid":true,"entries":2,"head":"ec6af1e8b869d84d6b7b6bb01179540fddcb3893d359528b0a2dadbd950d5bca"},"energy":{"passes":2,"tokens_in":16845,"tokens_out":2940,"tokens_total":19785,"cost_usd":0,"models":{"grok/grok-4.3":1,"owner":1},"head":"ec6af1e8b869d84d6b7b6bb01179540fddcb3893d359528b0a2dadbd950d5bca"},"provenance":[{"ts":"2026-06-29T22:43:46.729Z","model":"grok/grok-4.3","action":"write","prompt":"","input":"Write a data-first, evidence-graded article: Tirzepatide for Nerve Damage\nSlug: tirzepatide-nerve-damage\nAudience: readers researching peptide evidence for this specific condition or drug cross.\nRules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate human trials from rat studies from Reddit/X anecdotes. No medical claims. Repair-vs-suppression framing. register: source_ledger.\n\nENRICHMENT BRIEF (binding section logic — one ## per compound):\n{\"voice\":\"enrichment\",\"article_shape\":\"single_focus\",\"condition\":null,\"condition_key\":null,\"primary_peptide\":null,\"peptides_in_scope\":[{\"id\":\"tirzepatide\",\"name\":\"Tirzepatide\"}],\"drugs_in_scope\":[],\"weight_sensitive\":false,\"stimulant_context\":false,\"breaking_down\":{\"section_title\":\"What's breaking down\",\"degenerative_why\":[],\"degenerative_layers\":[],\"note\":\"No condition profile matched — infer degeneration layers from slug/title and ledger claims.\"},\"peptide_chains\":[{\"peptide\":\"tirzepatide\",\"name\":\"Tirzepatide\",\"section_title\":\"Why Tirzepatide might help you\",\"layer\":\"metabolic load / body weight\",\"steps\":[\"**What keeps failing:** Same mechanical overload pattern as other GLP-1 contexts at higher body weight.\",\"**What Tirzepatide is studied to do:** Studied for GLP-1/GIP weight loss — load reduction on spine and joints.\",\"**Therefore for you:** If that layer is part of your problem, Tirzepatide is discussed because it targets repair (metabolic load / body weight) — not because it masks pain.\"],\"prose\":\"1. **What keeps failing:** Same mechanical overload pattern as other GLP-1 contexts at higher body weight.\\n2. **What Tirzepatide is studied to do:** Studied for GLP-1/GIP weight loss — load reduction on spine and joints.\\n3. **Therefore for you:** If that layer is part of your problem, Tirzepatide is discussed because it targets repair (metabolic load / body weight) — not because it masks pain.\"}],\"drug_chains\":[],\"stimulant_chains\":[],\"stack_together\":\"Single-compound focus — if your condit","response":"{\n  \"slug\": \"tirzepatide-nerve-damage\",\n  \"title\": \"Tirzepatide for Nerve Damage: Evidence-Graded Review\",\n  \"body\": \"## What's breaking down\\n\\nNerve damage, often in the form of peripheral neuropathy, involves degeneration where repair pathways fall behind breakdown. In metabolic conditions like type 2 diabetes, high blood glucose drives oxidative stress, inflammation, and impaired nerve blood flow. This leads to axonal loss and reduced nerve fiber density over time. Excess body weight can add mechanical compression on nerves, such as the peroneal nerve at the knee during rapid shifts. The core issue is ongoing degeneration outpacing any natural repair signals in the peripheral nervous system.\\n\\n## Why Tirzepatide might help you\\n\\n1. What keeps failing: The same metabolic overload that damages nerves through sustained high glucose and inflammation also contributes to excess body weight that can compress peripheral nerves.\\n2. What Tirzepatide is studied to do: It activates GLP-1 and GIP receptors, producing substantial weight loss and improved glycemic control that lower overall metabolic stress on nerves.\\n3. Therefore for you: If metabolic load or body weight contributes to your nerve damage layer, Tirzepatide is discussed because it targets the underlying drivers of degeneration rather than only suppressing symptoms like pain.\\n\\n## How these fit together\\n\\nSingle-compound focus. Tirzepatide addresses the metabolic load and body weight layer. If your profile includes additional degeneration layers such as direct neural inflammation or sleep disruption, other compounds would target those separately without overlap in this review.\\n\\n## What the evidence actually shows\\n\\nHuman data on prevention: A large propensity score-matched database analysis of over 1 million type 2 diabetes patients found tirzepatide users had a lower cumulative incidence of new diabetic peripheral neuropathy at 2 years (3% vs 6.3% with insulin). Risk reductions were observed at 1 month","tokens_in":16845,"tokens_out":2940,"cost":0,"prev":"genesis","hash":"9abe1b3c6b966f9c96e4388928937f9d241387af91a940006e9a82e18950ac5e"},{"ts":"2026-07-17T02:43:17.743Z","model":"owner","action":"voxel_divide","prompt":"","input":"tirzepatide-nerve-damage","response":"21 DIVs from body (verbatim, roundtrip-checked)","tokens_in":0,"tokens_out":0,"cost":0,"prev":"9abe1b3c6b966f9c96e4388928937f9d241387af91a940006e9a82e18950ac5e","hash":"ec6af1e8b869d84d6b7b6bb01179540fddcb3893d359528b0a2dadbd950d5bca"}]}